Skip to content
DataLookout
Menu

NCT07912840

Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Area under the plasma drug concentration-time curve [AUCt]
Timeframe: 0-72 hours
Maximum plasma concentration [Cmax]
Timeframe: 0-72 hours

Secondary (4)

Area under the plasma drug concentration -time curve from 0 to infinity [AUCinf]
Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity [AUCt/AUCinf]
Time of peak concentration [Tmax]
Terminal phase of half-life [t1/2]

Arms and interventions

A(RTRT)Experimental

22 subjects, Cross-over, Single dose YHR2602 on period 1 and 3, Single dose of YHP2508B on period 2 and 4.

B(TRTR)Experimental

22 subjects, Cross-over, Single dose YHP2508B on period 1 and 3, Single dose of YHR2602 on period 2 and 4.

Drugs: YHP2508B, YHR2602

Sites

1 site in 1 country

  • Gimpo Woori HospitalGimpo-si, South Korea